

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

27 Jun 2026

### Evaluation of the effect of oral and vaginal isosorbide mononitrate and oral propranolol tablets on cervical preparation before induction in primiparous and term pregnancy

#### Protocol summary

##### Study aim

Evaluation of oral and vaginal tablets isosorbide mononitrate and oral propranolol tablets for Preinduction of Cervical Ripening in primiparous term pregnancy

##### Design

Clinical trial with control group, one-blind, randomized, phase three on 120 patients. Excel software random function was used for randomization

##### Settings and conduct

In a randomized single-blind randomized clinical trial 120 pregnant women of normal term with normal pregnancy and with a score of 2 or less who were referred to Yas Hospital in Tehran were selected and were randomly divided into four groups by random allocation. The intervention groups did not know the type of drug. Intervention groups included a group of vaginal isosorbide mononitrate (40 mg), one group of oral isosorbide mononitrate (40 mg), one group of oral propranolol tablets (20 mg), and one control group without the intervention. Cervical maturation was measured before and 24 hours after the intervention.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: 37-40 weeks gestation, primiparous, live fetus, single fetus, cephalic, intact membranes, Bishop score under two, fetal weight less than 4 kg. Exclusion criteria: History of headache, alcohol, preeclampsia, IUGR, polyhydramnios and oligohydramnios, placenta previa

##### Intervention groups

Intervention groups included a group of vaginal isosorbide mononitrate (40 mg), one group of oral isosorbide mononitrate (40 mg), one group of oral propranolol tablets (20 mg) and one control group without the intervention. 30 people were measured.

##### Main outcome variables

Method of delivery, time elapsed to dilation 6cm  
Duration elapsed time from dilatation 6 cm to full

dilation, Time elapsed from full dilation to delivery, Maternal complications, Bishop score change 24 hours after receiving the drug, Apgar 5 min, Cord pH, NICU hospitalization, meconium excretion, need for oxytocin to induce labor

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20201003048910N1**  
Registration date: **2020-10-18, 1399/07/27**  
Registration timing: **retrospective**

Last update: **2020-10-18, 1399/07/27**

Update count: **0**

##### Registration date

2020-10-18, 1399/07/27

##### Registrant information

##### Name

Mahnaz Tajpour

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 2278 5738

##### Email address

mahnaz\_tajpour@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2018-09-23, 1397/07/01

##### Expected recruitment end date

2019-09-23, 1398/07/01

**Actual recruitment start date**

2018-09-30, 1397/07/08

**Actual recruitment end date**

2019-10-22, 1398/07/30

**Trial completion date**

2019-10-22, 1398/07/30

**Scientific title**

Evaluation of the effect of oral and vaginal isosorbide mononitrate and oral propranolol tablets on cervical preparation before induction in primiparous and term pregnancy

**Public title**

Evaluation of the effect of oral and vaginal isosorbide mononitrate tablets and oral propranolol tablets on cervical preparation.

**Purpose**

Screening

**Inclusion/Exclusion criteria****Inclusion criteria:**

Includes 37-40 weeks gestation live fetus Noli Par single fetus cephalic intact membranes under two bishop scores fetal weight less than 4 kg normal fetal health monitoring result no uterine contractions There were no systemic problems in the history and clinical examination.

**Exclusion criteria:**

Abnormality of fetal appearance with pelvis or non-cephalic presence of uterine scar previous history of cesarean section history of cervical cone (conization) polyhydramnios history of drug allergy contraindications to vaginal delivery aginal bleeding during third trimester placenta previa multiple pregnancy suspected fetal abnormality bishop score above 3 uterine contractions uncertain NST chorioamnionitis history of asthma active genital herpes any contraindications to induction of labor systolic pressure less than 90 Cardiovascular disease severe preeclampsia alcoholism history of headache

**Age**

From **21 years** old to **30 years** old

**Gender**

Female

**Phase**

3

**Groups that have been masked**

- Outcome assessor

**Sample size**

Target sample size: **120**

Actual sample size reached: **120**

More than 1 sample in each individual

Actual sample size in each individual: **30**

The sample size was determined based on statistical formulas and 95% confidence level, 120 people, 30 people were considered for each group.

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

The primiparous term pregnancy who needed induction of labor due to termination of pregnancy and adverse cervix were easily selected and based on a random

number table into four groups of recipients of forty mg isosorbide vaginal mononitrate (n = 30) and oral isosorbide mononitrate. Forty mg (30) patients and 40 mg oral propranolol tablets (two 20 mg tablets every twelve hours to the dose (n = 30) and the control group (n = 30) were divided.

**Blinding (investigator's opinion)**

Single blinded

**Blinding description**

The person assessing the consequences is kept blind.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee in Research, School of Medicine, Tehran University of Medical Sciences

**Street address**

No18,deldar,baradaran rahmani avenu,sadr blv

**City**

Tehran

**Province**

Tehran

**Postal code**

1939963559

**Approval date**

2019-12-07, 1398/09/16

**Ethics committee reference number**

IR.TUMS.MEDICINE.REC.1398.641

**Health conditions studied****1****Description of health condition studied**

cervical ripening

**ICD-10 code****ICD-10 code description****Primary outcomes****1****Description**

cervical ripening

**Timepoint**

24 hours after the start of the study

**Method of measurement**

vaginal examination

## Secondary outcomes

### 1

#### **Description**

Duration of the first phase of labor (including latent and active phase)

#### **Timepoint**

During the study

#### **Method of measurement**

Observation and examination

### 2

#### **Description**

Duration of the second stage of labor (from complete dilatation to fetal delivery )

#### **Timepoint**

During the study

#### **Method of measurement**

Observation and examination

### 3

#### **Description**

Duration of the third stage of labor (from the time of embryo departure to complete placental abruption)

#### **Timepoint**

During the study

#### **Method of measurement**

Observation and examination

### 4

#### **Description**

Method of childbirth

#### **Timepoint**

During the study

#### **Method of measurement**

Observation and examination

### 5

#### **Description**

Maternal complications (headache, nausea, vomiting and dizziness)

#### **Timepoint**

During the study

#### **Method of measurement**

Observation and examination

### 6

#### **Description**

Neonatal outcomes (first and fifth minute Apgar score, umbilical cord PH, neonatal hospitalization in intensive care unit)

#### **Timepoint**

During the study

#### **Method of measurement**

Observation and examination

## Intervention groups

### 1

#### **Description**

In the first group, single dose of 40 mg of isosorbide mononitrate from Aria drug will be placed vaginally in the posterior fornix by the researcher.

#### **Category**

Treatment - Devices

### 2

#### **Description**

In the second group single dose of 40 mg Isosorbide mononitrate tablets are given orally from Aria Pharmaceutical Company.

#### **Category**

Treatment - Devices

### 3

#### **Description**

Oral propranolol tablets are given orally at single dose of 20 mg from Dr. Obidi Pharmaceutical Company.

#### **Category**

Treatment - Devices

### 4

#### **Description**

Control group: The control group is given 24 hours to soften the cervix and no medication is prescribed.

#### **Category**

Other

## Recruitment centers

### 1

#### **Recruitment center**

##### **Name of recruitment center**

Yas Comprehensive Women's Hospital

##### **Full name of responsible person**

Mahnaz Tajpour

##### **Street address**

Karim Khan, North Villa

##### **City**

Tehran

##### **Province**

Tehran

##### **Postal code**

1939963559

##### **Phone**

+98 21 8885 3038

##### **Email**

yashospital@gmail.com

## Sponsors / Funding sources

## 1

### Sponsor

**Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Mahnaz Tajpour

**Street address**

Karim Khan, North Villa

**City**

Tehran

**Province**

Tehran

**Postal code**

1939963559

**Phone**

+98 21 8885 3038

**Email**

yashospital@gmail.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

No

**Title of funding source**

drug

**Proportion provided by this source**

10

**Public or private sector**

Private

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Other

### Person responsible for general inquiries

**Contact****Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Mahnaz Tajpour

**Position**

resident

**Latest degree**

Specialist

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

Karim Khan, North Villa

**City**

tehran

**Province**

Tehran

**Postal code**

1939963559

**Phone**

009822785738

**Email**

mahnaz\_tajpour@yahoo.com

### Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

mahnaz tajpour

**Position**

resident

**Latest degree**

Specialist

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

Karim Khan, North Villa

**City**

Tehran

**Province**

Tehran

**Postal code**

1939963559

**Phone**

+98 21 2278 5738

**Email**

mahnaz\_tajpour@yahoo.com

### Person responsible for updating data

**Contact****Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

MAHNAZ TAJPOUR

**Position**

RESIDENT

**Latest degree**

Specialist

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

Karim Khan, North Villa

**City**

tehran

**Province**

Tehran

**Postal code**

1939963559

**Phone**

009822785738

**Email**

mahnaz\_tajpour@yahoo.com

### Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to

make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available